Vigil™ Vaccine

BIOLOGICAL4 trials

Sponsors

Gradalis, Inc.

Conditions

Advanced MelanomaColon CancerStage III Ovarian CancerStage IV Ovarian Cancer

Phase 2

Phase II FANG™ in Advanced Melanoma

TerminatedNCT01453361

Gradalis, Inc.Advanced Melanoma

Start: 2011-10-31End: 2016-03-22Updated: 2018-05-24

Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases

TerminatedNCT01505166

Gradalis, Inc.Colon Cancer

Start: 2012-03-31End: 2016-08-31Updated: 2021-11-01

Salvage Ovarian FANG™ Vaccine + Bevacizumab

CompletedNCT01551745

Gradalis, Inc.Stage III Ovarian Cancer, Stage IV Ovarian Cancer

Start: 2012-03-31End: 2016-04-30Updated: 2021-10-19

Salvage Ovarian FANG™ Vaccine + Carboplatinum

CompletedNCT01867086

Gradalis, Inc.Stage III Ovarian Cancer, Stage IV Ovarian Cancer

Start: 2013-06-30End: 2016-04-08Updated: 2018-06-19

Related Papers

Long-Term Survival and Immune Response Dynamics in Melanoma Patients Undergoing TAPCells-Based Vaccination Therapy

Vaccines2024-03-275 citations

New advances in cancer therapy targeting TGF-β signaling pathways

Molecular Therapy — Oncolytics2023-12-0127 citations

Survival effect of bi-shRNA<sup>furin</sup>/GMCSF DNA-based immunotherapy (FANG) in 123 advanced cancer patients to α-interferon-ELISPTOT response.

Journal of Clinical Oncology2014-05-202 citations